Amgen Stock Jumps on Earnings Beat, Guidance Boost

Shares of Amgen were falling Tuesday after the biotechnology company easily beat quarterly earnings estimates and lifted revenue guidance.

Third-quarter sales of inflammation drug Amjevita/Amgevita rose 30% year-over-year, bolstered by 53% volume growth, partially offset by lower prices, according to the release, while sales of Prolia, one of Amgen’s general medicine treatments, jumped 14% from a year ago, boosted by a 7% uptick in volume and higher prices.

Nederland Laatste Nieuws, Nederland Headlines

Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.

Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Bron: MarketWatch - 🏆 3. / 97 Lees verder »

Arista Stock Jumps as Earnings Top EstimatesInvestors had worried about the outlook after Meta Platforms issued a more conservative capital-spending forecast than expected.
Bron: MarketWatch - 🏆 3. / 97 Lees verder »

Dow jumps more than 300 points ahead of Fed rate decision, earningsCertain parts of the economy have proved to be resilient, spurring concerns that the central bank could signal willingness to hold rates at their current level for longer than previously anticipate…
Bron: nypost - 🏆 91. / 67 Lees verder »